Lack of Response to Intravitreal Ranibizumab Treatment in Adult Onset Foveomacular Vitelliform Dystrophy Complicated with Choroidal Neovascularization: A Case Report. Cesk Slov Oftalmol 2025;81(1):38-40
Date
06/27/2024Pubmed ID
38925903DOI
10.31348/2024/21Scopus ID
2-s2.0-105019787623 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Adult-onset foveomacular vitelliform dystrophy (AOFVD) is a rare disease characterized by accumulation of yellowish deposits in the macula. Rarely, it may be complicated by choroidal neovascularization (CNV). Cases with CNV may be confused with occult CNV in age-related macular degeneration. In our case, we will present the visual and anatomical results of a patient with AOVF-related CNV, in which we administered 3 doses of intravitreal ranibizumab (IVR). A 59-year-old female patient, who attended our clinic with the complaint of decreased vision in both eyes, was diagnosed with AOVF-related CNV in both eyes and was treated with 3 doses of IVR for 3 months. Despite the improvement in visual and anatomical functions 1 month after the first dose, vision decreased, and anatomical functions regressed to the pre-injection state in continued injections. IVR therapy is not an appropriate treatment option in the treatment of AOVF-associated CNV.
Author List
Berhuni M, Tıskaoğlu NS, Ozturkmen CAuthor
Nesime Setge Tiskaoglu MBBS Instructor in the Ophthalmology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Angiogenesis InhibitorsAntibodies, Monoclonal, Humanized
Choroidal Neovascularization
Female
Humans
Intravitreal Injections
Middle Aged
Ranibizumab
Vitelliform Macular Dystrophy
